A Caelyx helye a petefészekrák másodvonalbeli kezelésében

Magyar Onkologia

Volumn 48, Issue 1, 2004, Pages 97-99

  Tamás, Pulay ^{a,b,c,d,e,f,g,h,i,j}   Sándor, Csömör ^{a,b,c,d,e,f,g,h,i}   Zsolt, Faluhelyi ^{a,b,c,d,e,f,g,h,i}   Zoltán, Hernádi ^{a,b,c,d,e,f,g,h,i}   Károly, Krommer ^{a,b,c,d,e,f,g,h,i}   Árpád, Mayer ^{a,b,c,d,e,f,g,h,i}   András, Szánthó ^{a,b,c,d,e,f,g,h,i}   István, Szántó ^{a,b,c,d,e,f,g,h,i}   László, Thurzó ^{a,b,c,d,e,f,g,h,i}  

^a Mellkasi és Hasüregi Daganatok Kemoterápia B és Klinikai Farmakológiai Osztály   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Baranya Megyei Kórház Onkológiai Osztály   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e UNIVERSITY OF PÉCS   (Hungary)

^f Onkoradiológiai Központ   (Hungary)

^g Intézményei Onkológiai Szakrendelés   (Hungary)

^h UNIVERSITY OF SZEGED   (Hungary)

ⁱ Gyógyszerésztudományi Centrum Onkoterá piás Klinika   (Hungary)

^j NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874976413     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bajetta E. NICE Technology Appraised Guidance No 45. Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer.
2. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9:1343-1345, 1998
3. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 20:3312-3322, 2001
4. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxelrefractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000
5. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
6. Hubbard SM, Barkes P, Young RC. Adriamycin therapy for advanced ovarian carcinoma recurrent after chemoterapy. Cancer Treat Rep 62:1375-1377, 1978
7. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
8. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 380:561-562, 1996
9. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
10. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi sarcoma. J Clin Pharmacol 36:55-63, 1996
11. Ozols RF, Schwartz PE, Eifel PJ. Treatment of advancedstage ovarian cancer. In: Cancer: Principles and Practice of Oncology. Eds: DeVita VT, Hellman S, Rosenberg SA et al. Philadelphia, PA: Lippincott-Raven 1997 pp 1514-1539
12. Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 91:90-100, 2001
13. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033, 2000
14. Smith PJ, Soues S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer 23(Suppl.):S47-S51, 1994
15. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 7:1672-1676, 1989
16. Tejada-Bergers T, Granai CO, Gordiner M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarium and breast cancer. Expert Rev Anticancer Ther 2:143-150, 2002
17. ten Bokken Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
18. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 99:745-749, 1999
19. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicites during two complementary Phase I studies. J Clin Oncol 13:1777-1785, 1995
20. Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylmelamine as second-line therapy in platinresistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
21. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979